

Title (en)

FUMARIC ACID DERIVATIVES AS NF-KAPPAB INHIBITORS

Title (de)

FUMARSÄUREDERIVATE ALS NF-KAPPAB-INHIBTOREN

Title (fr)

DERIVES DE L'ACIDE FUMARIQUE UTILISES COMME INHIBITEURS NF-KAPPAB

Publication

**EP 1408947 A2 20040421 (DE)**

Application

**EP 02712806 A 20020108**

Priority

- DE 10101307 A 20010112
- EP 0200108 W 20020108

Abstract (en)

[origin: WO02055067A2] The invention relates to the use of at least one fumaric acid derivative as an NF-kappaB inhibitor. The invention also relates to the use of fumaric acid derivatives for producing a pharmaceutical preparation for the treatment of disorders which can be influenced by NF-kappaB.

IPC 1-7

**A61K 31/194; A61K 31/225; A61P 1/04; A61P 1/16; A61P 9/00; A61P 11/00; A61P 13/12; A61P 17/00; A61P 19/02; A61P 19/06; A61P 31/00; A61P 35/00**

IPC 8 full level

**A61K 9/16 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 9/48 (2006.01); A61K 9/50 (2006.01); A61K 9/62 (2006.01); A61K 31/194 (2006.01); A61K 31/225 (2006.01); A61K 47/04 (2006.01); A61K 47/12 (2006.01); A61K 47/32 (2006.01); A61K 47/36 (2006.01); A61K 9/22 (2006.01); A61K 47/38 (2006.01); A61P 1/04 (2006.01); A61P 1/16 (2006.01); A61P 9/00 (2006.01); A61P 9/10 (2006.01); A61P 11/00 (2006.01); A61P 13/12 (2006.01); A61P 17/00 (2006.01); A61P 19/02 (2006.01); A61P 19/06 (2006.01); A61P 19/08 (2006.01); A61P 25/00 (2006.01); A61P 31/00 (2006.01); A61P 31/04 (2006.01); A61P 31/12 (2006.01); A61P 35/00 (2006.01); A61P 39/02 (2006.01)**

CPC (source: EP US)

**A61K 9/1652 (2013.01 - EP US); A61K 9/2059 (2013.01 - EP US); A61K 9/2846 (2013.01 - EP US); A61K 9/4808 (2013.01 - EP US); A61K 9/5026 (2013.01 - EP US); A61K 31/194 (2013.01 - EP US); A61K 31/225 (2013.01 - EP US); A61P 1/00 (2018.01 - EP); A61P 1/04 (2018.01 - EP); A61P 1/16 (2018.01 - EP); A61P 1/18 (2018.01 - EP); A61P 3/10 (2018.01 - EP); A61P 9/00 (2018.01 - EP); A61P 9/10 (2018.01 - EP); A61P 11/00 (2018.01 - EP); A61P 13/10 (2018.01 - EP); A61P 13/12 (2018.01 - EP); A61P 17/00 (2018.01 - EP); A61P 19/00 (2018.01 - EP); A61P 19/02 (2018.01 - EP); A61P 19/06 (2018.01 - EP); A61P 19/08 (2018.01 - EP); A61P 25/00 (2018.01 - EP); A61P 27/02 (2018.01 - EP); A61P 31/00 (2018.01 - EP); A61P 31/04 (2018.01 - EP); A61P 31/12 (2018.01 - EP); A61P 35/00 (2018.01 - EP); A61P 35/02 (2018.01 - EP); A61P 39/02 (2018.01 - EP); A61P 43/00 (2018.01 - EP)**

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

**WO 02055067 A2 20020718; WO 02055067 A3 20040226; AU 2002244638 B2 20050505; BG 107829 A 20041230; BR 0206381 A 20040803; CA 2428075 A1 20020718; CN 1520291 A 20040811; CZ 20031918 A3 20040414; DE 10101307 A1 20020801; EE 200300281 A 20031015; EP 1408947 A2 20040421; HU P0302650 A2 20031128; HU P0302650 A3 20090828; IL 156849 A0 20040208; JP 2004528281 A 20040916; JP 2009073854 A 20090409; MX PA03006248 A 20040402; NO 20031450 D0 20030328; NO 20031450 L 20030912; NZ 525148 A 20060630; PL 363603 A1 20041129; RU 2003124751 A 20050110; RU 2282440 C2 20060827; SK 8252003 A3 20031202; US 2004054001 A1 20040318; US 2008233185 A1 20080925; WO 02055066 A1 20020718; YU 55903 A 20060817; ZA 200305343 B 20040817**

DOCDB simple family (application)

**EP 0200108 W 20020108; AU 2002244638 A 20020108; BG 10782903 A 20030520; BR 0206381 A 20020108; CA 2428075 A 20020108; CN 02803628 A 20020108; CZ 20031918 A 20020108; DE 10101307 A 20010112; EE P200300281 A 20020108; EP 0104454 W 20010419; EP 02712806 A 20020108; HU P0302650 A 20020108; IL 15684902 A 20020108; JP 2002555801 A 20020108; JP 2008290821 A 20081113; MX PA03006248 A 20020108; NO 20031450 A 20030328; NZ 52514802 A 20020108; PL 36360302 A 20020108; RU 2003124751 A 20020108; SK 8252003 A 20020108; US 25098303 A 20030710; US 83315007 A 20070802; YU P55903 A 20020108; ZA 200305343 A 20030710**